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Abstract
Objective: To determine pregnancy loss rate following amniocentesis in a mainstream urban healthcare centre.
Methods: We analysed cases of all pregnant women who underwent Amniocentesis at the Foetal Medicine Unit
of Aga Khan University Hospital, Karachi, during 2001 to 2010. Cases of unknown pregnancy outcome were
excluded, and after the process of consent, the final study population was 228 patients. Two operators performed
the procedure using 22 G needle. 
Results: The mean age of women in the study was 32±6 years. The commonest indication of the procedure was
a previous baby with Down's Syndrome. Majority 197 (86.6%) cases had a normal karyotype. Down's syndrome
was 14 (6.1%). Regarding the outcome of pregnancies, it was normal in 173 (77.3%) cases while 2 (0.8%)
intrauterine deaths were reported, one of which was within two weeks of the procedure. The number of
pregnancy termination was 27 (11.7%). There was one miscarriage which means the pregnancy loss rate in the
study population was 0.4%.
Conclusion: In order to have good quality control, healthcare audits are essential on both short-term and long-
term basis.
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Introduction
Amniocentesis is the most commonly performed
invasive procedure in Foetal Medicine. It is performed from
16 weeks of pregnancy. The primary purpose of the
procedure remains chromosomal analysis, the results of
which are then used in the counselling of couples and
discussion about the options available for pregnancies
complicated with chromosomal abnormalities.
The counselling of women for an invasive procedure
is based on her likelihood of having a baby with
chromosomal abnormality versus the risk of procedure-
related miscarriage. The risk of miscarriage was reported to
be between 0.5-1%.1-3 This figure is based on the results of
some case controlled studies1,2 and a single randomised
controlled trial done on low-risk women population in the
1980s.3
The technique of Amniocentesis has come a long
way since its introduction in the 1970s. Now almost all such
procedures are performed under continuous ultrasound
guidance and, therefore, the risk of miscarriage is even less
than that reported in the literature.1,2As the expertise of this
procedure has improved considerably, an increasing number
of women above the age of 35 are opting for this procedure.
In several countries routine serum screening or Nuchal
Translucency screening is in place,4 which identifies high-
risk women who need invasive testing. This approach has
resulted in reduced number of invasive procedures.5
Although Amniocentesis is a commonly performed
procedure, but it is important to ensure that standards are
being followed. The aim of this study was to determine the
risk of miscarriage with Amniocentesis and to monitor the
performance of this service at our unit.
Patients and Methods
The observational cohort study used data of all
Amniocentesis cases performed during 2001 to 2010 at the
Foetal Medicine Unit of AKUH. We included all women
who underwent the procedure during this time. However,
given the geographical diversity of the patients attending the
unit, it was difficult to follow up all pregnancy outcomes. We
excluded cases with unknown pregnancy outcomes and
those who were not willing to participate in the study. 
The study was approved by the Ethical Review
Committee of the Aga Khan University Hospital. As part of
the policy, every referred woman to the FMU is requested to
sign consent to allow the use of their information with
confidentiality. Additional consent, however, was obtained
prior to the procedure. In addition to the demographic
characteristics, we noted the main indications for the
procedure, which included: Advanced maternal age;
Positive maternal serum screening; Previous baby affected
by Down's Syndrome; Previous baby with other
chromosomal abnormality; Suspicious ultrasound findings
in the current pregnancy; Family history of chromosomal
abnormalities; Triple test results; and any other observation.
All patients who were referred to our unit underwent
an ultrasound scan prior to the procedure. Initially we used
Toshiba Nemio machine (Tokyo, Japan) and later on
Medison Accuvix (Seoul, Korea). Following the ultrasound,
they were counselled about the procedure and due consent
was obtained. As a routine we checked the rhesus status. 
Two trained operators performed Amniocentesis in
our unit, using 20 G spinal needle. The first 1 ml was
discarded to minimise the contamination with the mother's
blood cells and then 16 mls were removed and sent for
Fluorescence In Situ Hyperdisation (FISH) and Karyotype.
During the procedure a local anaesthetic was also given. 
The patients were counselled about the complications
of the procedure and given information leaflet and contact
numbers prior to discharge. They were also encouraged to
keep us informed about the outcome of the pregnancy.
For statistical analysis, descriptive measures were
used to analyze the categorical data. Frequencies and
percentages were used for result of amniocentesis.
Results
A total number of 228 patients were part of the
study. The mean age of women in the study was 32±6
years. Out of the study subjects, 89 (38.8%) were above 35
years of age.
Over half of the Amniocentesis procedures were
performed between 16 and 18 weeks of gestation (n=129;
56.8%). Indications of the procedures performed in our unit
were separately noted (Table-1).
There was culture failure in three of the initial
samples. The procedure failed in one case where it had to be
repeated. The rate of miscarriage was 0.4% (n=1) (Table-2).
The study cohort was followed up till delivery and
outcomes were recorded, showing 173 (77.3%) livebirths.
There were 2 (0.8%) cases of IUD post Amniocentesis, one
of which was within two weeks of the procedure,
accounting for 0.4% of the pregnancy loss rate in the study
cohort. In the other case the pregnancy was complicated
with multiple anomalies and resulted in foetal demise at 26
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Table-1: Indication of Amniocentesis.
Indication Number (%)
Advanced maternal age 43 18.9
Previous Down's baby 68 29.8
Increased Nuchal Tranlucency 4 1.8
Previous history of structural abnormal baby 13 5.7
Triple test positive 34 14.9
Family history of congenital abnormalities 6 2.6
Abnormality in present pregnancy 23 10.1
Previous chromosomal abnormal baby 22 9.6
Thalasemia 15 6.6
Total 228 100.0
Table-2: Results of Amniocentesis.
Test result Frequency Percent%
Normal karyotyping 197 86.4
Trisomy 21 14 6.1
Trisomy 18 5 2.6
Thalasaemia major 6 2.3
Thalasaemia minor 1 0.4
Technically failed 4 1.8
Triploidy 1 0.4
Total 228 100.0
weeks. Among the study subjects, 27 (11.7%) cases
underwent termination of pregnancy (Figure).
Discussion
Amniocentesis is the most common invasive
procedure performed in foetal medicine. It was introduced
in the 1970s.1,2 The main purpose to undertake this test is
for the determination of foetal karyotype. Apart from the
diagnosis of chromosomal abnormalities, it can be used in
some genetic abnormalities. In our study, the majority
underwent Amniocentesis for the determination of
karyotype. The procedure is commonly performed between
16-20 weeks. In our study over half of the women (56.8%)
underwent Amniocentesis before 18 weeks of gestation. 
The procedure-related risk of Amniocentesis has
been extensively studied by many researchers. The report of
the British Medical Research Council is one of the earliest
one where the miscarriage rate was 0.9%.1 The only
randomised controlled trial was that reported by Tabor et.al
in 1970s which reported it to be 0.7%.3 Other studies
published have also reported the risk to be 0.5-1%.6-10 In our
study, the risk was 0.4%.
The miscarriage risk also depends on the gestational
age at which the procedure is performed and is much higher
if the procedure is performed before 14 weeks. None of the
patients at our unit underwent early Amniocentesis.
The risk of Amniocentesis-related miscarriage is
over and above the background risk of miscarriage. The risk
of spontaneous miscarriage quoted is around 1%. Therefore,
the risk of procedure-related miscarriage is not more than
the background risk in our study.
The other common complications reported with this
procedure are the risk of bleeding, abdominal cramping and
leaking. The risk of leaking following the procedure has been
reported to be 1%.8 However, there was no case complicated
with leaking in our study. Similarly, there was no case of Talipes.
The majority of chromosomal abnormalities
reported in the pre-natal diagnosis are of Trisomy 21, 18 or
13 and sex chromosome aneuploidies.6 Therefore, the
predominant reason for Amniocentesis is to rule out these
abnormalities, in particular Down's Syndrome. Eighty
percent of women in our study population underwent
Amniocentesis for the same. 
Three of the cases had culture failure in our initial
cases, accounting for 1.3%. The success rate of the specimens
is consistent with that reported by others.7,11The results of the
study are consistent with the other reported literature and our
complication rate is also within acceptable limits.
Conclusion 
In order to have good quality control, such audits
need to be conducted regularly. Unfortunately a vast
majority of patients coming to our unit happen to be either
from other cities or from other hospitals in the city. As such,
following the outcome remains a great challenge.
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Figure: Details of termination of pregnancy.
